Frontlight ResearchEarly access
CompletedNo phase
Multicentric Clinical Study on Isatis TF Trifocal Intraocular Lens
Key facts
- Who runs it
- Cutting Edge SAS
- Where
- Czechia and Spain7 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 188 people enrolled
- Started
- 31 May 2021
- Ended
- 27 Jun 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Implantation of trifocal IOL, Isatis TF (device under investigation)
- Implantation of monofocal IOL, Isatis (control device)
- Record updated
- 12 February 2025
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Clinically documented age-related cataract in both eyes with no comorbidity
- Calculated IOL power is within the range of the investigational IOLs
- Male or female adults ages 50 years or older on the day of screening who have cataracts in both eyes
- Regular corneal astigmatism (measured by topographer)
- Astigmatism ≤1.0 D (measured by an automatic keratometer)
- Clear intraocular media other than cataract
- Availability, willingness and sufficient cognitive awareness to comply with examination procedures
- Patient is willing to receive bilateral implantation of a trifocal IOL (this inclusion criteria applies only to the study group, not the control group)
- Signed informed consent
Who cannot take part
- Previous intraocular or corneal surgery
- Expected complicated surgery
- Concurrent participation in another drug or device investigation; In addition to above mentioned in- and exclusion criteria, subjects shall be discontinued when certain conditions are present at the time of surgery, including:
- Difficulty for cooperation (distance from their home, general health conditions)
- Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal or optic disorders)
- Ocular hypertension, suspicious glaucoma or glaucoma
- Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic / scotopic conditions)
- Ocular surface disease (clinical symptoms or keratitis)
- inability to fixate IOL in desired position. In such cases, the subject shall be followed until the condition has stabilized
- Age of patient < 50 years
- Regular corneal astigmatism >1.0 dioptres (measured by an automatic keratometer)
- Irregular astigmatism (measured by topographer)
- Subjects with AMD suspicious eyes as determined by OCT examination
- Traumatic cataract
- Instability of keratometry or biometry measurements; Acceptable maximum standard deviation: AL: ± 150 µm; ACD: ± 150 µm; K1 / K2: ± 0.15 D
- Pregnancy or lactation
- Second eye treatment will only be performed when Best Corrected Distance Visual Acuity (CDVA) of first eye is ≤ 0.2 logMAR (≥ 0.63 decimal)
- zonular instability
- need for iris manipulation
- capsular fibrosis or other opacity; and
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study will be a multicentric, prospective open-label ethics committee approved clinical study to investigate safety, visual outcomes, contrast sensitivity and rotational stability after bilateral implantation of Isatis TF IOL following cataract surgery.
The 2 groups in the trial
- IOL implantation experimentalTreatment being tested
Experimental arm: Trifocal intraocular lens Isatis TF
Treatment: Implantation of trifocal IOL, Isatis TF (device under investigation)
- IOL implantation active comparatorExisting treatment, for comparison
Comparator arm: Monofocal intraocular lens Isatis
Treatment: Implantation of monofocal IOL, Isatis (control device)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicentric Clinical Study to Determine Safety and Efficacy of a Hydrophobic Acrylic Trifocal Intraocular Lens (IOL)
- Record updated
- 12 February 2025